Richard S. Levy Acquires 3,550 Shares of Madrigal Pharmaceuticals Inc (MDGL) Stock
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Director Richard S. Levy acquired 3,550 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average price of $16.12 per share, with a total value of $57,226.00. Following the completion of the acquisition, the director now owns 3,640 shares of the company’s stock, valued at approximately $58,676.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Madrigal Pharmaceuticals Inc (NASDAQ MDGL) traded up 0.7419% on Friday, hitting $17.0153. The company had a trading volume of 1,857 shares. Madrigal Pharmaceuticals Inc has a one year low of $9.30 and a one year high of $18.24. The company’s market capitalization is $212.61 million. The stock’s 50-day moving average price is $15.76 and its 200 day moving average price is $15.71.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.09. On average, analysts expect that Madrigal Pharmaceuticals Inc will post ($2.57) EPS for the current fiscal year.
Separately, ValuEngine upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 19th.
Large investors have recently made changes to their positions in the stock. New York State Common Retirement Fund purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $109,000. California State Teachers Retirement System purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $117,000. TIAA CREF Investment Management LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $120,000. Bank of New York Mellon Corp purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $179,000. Finally, Citigroup Inc. purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter valued at $185,000. 12.58% of the stock is owned by institutional investors.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Stock Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.